Literature DB >> 2766755

Paradoxical elevation of pulmonary vascular resistance after nifedipine in primary pulmonary hypertension. A case study.

B Pohar1, A Grad, M Mozina, P Rakovec, M Horvat.   

Abstract

The case of a 55-year-old woman with primary pulmonary hypertension is described who developed 2 hours after sublingual administration of a 10 mg capsule of nifedipine a severe rise in pulmonary arterial and right atrial pressures accompanied with dyspnoea and cyanosis. The event lasted for two hours and subsided without intervention. With repeated nifedipine intake in the form of orally administered slow-release tablets no complications occurred. The authors ascribe the marked rise in pulmonary vascular resistance to rapid reduction of plasma nifedipine concentration after sublingual administration, due to a faster drug resorption compared to oral intake. The necessity of cautious introduction of vasodilating drugs in pulmonary hypertension and of gradual dosage increase is stressed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2766755

Source DB:  PubMed          Journal:  Cor Vasa        ISSN: 0010-8650


  2 in total

1.  Stump classification was correlated with retear in the suture-bridge and double-row repair techniques for arthroscopic rotator cuff repair.

Authors:  Naohide Takeuchi; Naoya Kozono; Akihiro Nishii; Koumei Matsuura; Eiichi Ishitani; Toshihiro Onizuka; Yoshihisa Zaitsu; Takamitsu Okada; Yasuhiro Mizuki; Takehiro Kimura; Hidehiko Yuge; Taiki Uchimura; Kunio Iura; Tatsuya Mori; Koki Ueda; Go Miake; Takahiro Senju; Kenji Takagishi; Yasuharu Nakashima
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-01-18       Impact factor: 4.342

Review 2.  Pharmacological implications of the Ca(2+)/cAMP signaling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders.

Authors:  Afonso Caricati-Neto; Antonio G García; Leandro Bueno Bergantin
Journal:  Pharmacol Res Perspect       Date:  2015-09-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.